Ascierto, Paolo A. https://orcid.org/0000-0002-8322-475X
Butterfield, Lisa H.
Demaria, Sandra
Ferris, Robert L.
Freeman, Gordon J.
Lo, Roger S.
Mantovani, Alberto
Nathan, Paul
Hamid, Omid
Politi, Katerina
Puzanov, Igor
Article History
Received: 10 April 2019
Accepted: 18 July 2019
First Online: 15 August 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Paolo A. Ascierto (PAA): Consultant/advisory relationship – Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono, Pierre-Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofy, Idera, Ultimovacs, Sandoz, Immunocore. Research funding – Array, Bristol-Myers Squibb, Roche-Genentech. Travel Support – MSD.Lisa H. Butterfield (LHB): Scientific and Medical Advisory Board – Simpatica, StemImmune, SapVax, NextCure, Replimmune, Western Oncolytics, Torque Therapeutics.Sandra Demaria (SD): Advisory Board/Research grant - Lytix Biopharma, Nanobiotix SA. Consultant - AbbVie Inc., AstraZeneca AB, EMD Serono, Cytune Pharma.Robert L. Ferris (RLF): Advisory Board/Clinical Trial/Research Funding – Amgen, Astra-Zeneca, Bristol-Myers Squibb, MedImmune, EMD Serono, Oncorus, Inc., PPD (Benitec, Immunicum), Lilly, Merck, Pfizer, Regeneron Pharmaceuticals, Inc., Tesaro, VentiRx Pharmaceuticals. Consulting - Bain Capital Life Sciences, Iovance Biotherapeutics, Inc., Ono Pharmaceutical Co. Ltd.Gordon J. Freeman (GJF): Intellectual Property related to the PD-1 / PD-1 Ligand pathway licensed non-exclusively to: Bristol-Myers-Squibb, Roche, Merck, Merck-Serono, Boehringer-Ingelheim, AstraZeneca, Dako, Novartis. Intellectual Property related to TIM-3 licensed to Novartis. Consultant - Bristol-Myers Squibb, Roche, Xios, Quiet, Origimed.Roger S. Lo (RSL): Research funding - OncoSec, Novartis, Merck. Research funding drug-only – Plexxicon, BeiGene, Genentech. Clinical trial funding – Array. Consultant - Shire, Array, Amgen, Merck.Alberto Mantovani (AM): Inventor of patents related to PTX3 and other innate immunity molecules. Royalties on IP and reagents. Advisory Boards/lecturing/consultancy - Efranat, Novartis, Roche, Ventana, Pierre Fabre, Verily, Abbvie, Compugen, Macrophage Therapeutics, Astra Zeneca, biovelocita, BG Fund. Grant support - Sigma-Tau, Roche, Novartis, Compugen, Efranat.Paul Nathan (PN): Astrazeneca, Bristol-Myers Squibb, Immunocore, Ipsen, Incyte, MSD, Merck, Novartis, Pfizer, Pierre Fabre, Roche.Omid Hamid (OH): Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono. Expert Testimony – Genentech. Other - Bristol-Meyers Squibb, Novartis, Array.Katerina Politi (KP): Co-Inventor on a Patent Licensed to Molecular MD for EGFR T790 M mutation testing (through MSKCC). Honoraria/Consulting: Takeda, NCCN, Novartis, Merck, AstraZeneca, Tocagen, Maverick Therapeutics and Dynamo Therapeutics. Research Support - AstraZeneca, Kolltan, Roche, Gilead, Symphogen.Igor Puzanov (IP): Consultant – Amgen, Roche, Abbvie.